Shah Trades

Swing Trader • Live Trade Tracking • Trade Ideas & Market Structure • Healthcare Finance & Sector Strategy • Financial Oncology Research • Not Financial Advice

[Shah Trades @ShahTrades]

September's opened with a real string of oncology wins. Revolution Medicines got Rasonque approved for pancreatic cancer and nearly doubled median survival in the trial, 13.2 months versus 6.7 on chemo, which is a rare thing to see in that disease. AbbVie's etentamig hit both primary endpoints for relapsed myeloma with a 74% response rate. Bristol Myers landed accelerated approval on Zenbexus, their first CELMoD therapy, another myeloma entrant. Multiple myeloma is turning into the most crowded, most competitive fight in oncology right now, worth watching how pricing and share shake out between BMY, ABBV and the rest of that field.

On the deal side, Roche paid $1.53B total for a trispecific antibody out of a Chinese biotech, and Lilly dropped $2.875B on Merida Biosciences for precision immunology. Big pharma's still buying pipeline instead of building it.

Rougher side of the month: Blueprint Medicines cut more than half its workforce, one of several biotechs doing deep layoffs recently. And Treasury just flagged $17.5B in suspected healthcare fraud today, that's a headline that'll have policy legs the rest of September.

What I'm actually watching through month end: $AXSM has its AXS-12 decision for Alzheimer's-related agitation coming, and from what's being modeled the approval odds aren't great, so that's real binary risk sitting on a stock that's already had a huge year. $MRK has a WINREVAIR update decision on the 21st. $NUVL has another lung cancer decision on the 18th. PDUFA season stacks up fast this time of year, and any one of those can move 20%+ in a day depending which way it breaks.

[Shah Trades @ShahTrades]

$BBC is Virtus's clinical-stage biotech ETF, tracking the LifeSci Biotechnology Clinical Trials Index built by LifeSci Index Partners in New York. Virtus runs the fund through its ETF Solutions arm, launched back in 2014.

The mandate is narrow. Every holding has to have its lead drug still in Phase 1, 2, or 3, nothing already commercial. 131 holdings, roughly equal weighted, top 10 names only about 12% of the fund. Current leaders are Amylyx, First Tracks Biotherapeutics, AbCellera, Xencor, and Monopar, no single name dominating.

The structural piece that matters: once a drug clears the FDA, that company gets rotated out of the index entirely. The fund stays perpetually early stage by design instead of accumulating names that already made it. It's a bet on the pipeline staying productive, not on any one company graduating.

[Shah Trades @ShahTrades]

$BBC is Virtus's clinical-stage biotech ETF, tracking the LifeSci Biotechnology Clinical Trials Index built by LifeSci Index Partners in New York. Virtus runs the fund through its ETF Solutions arm, launched back in 2014.

The mandate is narrow. Every holding has to have its lead drug still in Phase 1, 2, or 3, nothing already commercial. 131 holdings, roughly equal weighted, top 10 names only about 12% of the fund. Current leaders are Amylyx, First Tracks Biotherapeutics, AbCellera, Xencor, and Monopar, no single name dominating.

The structural piece that matters: once a drug clears the FDA, that company gets rotated out of the index entirely. The fund stays perpetually early stage by design instead of accumulating names that already made it. It's a bet on the pipeline staying productive, not on any one company graduating.

[Shah Trades @ShahTrades]

@StockSavvyShay Same capex, same numbers, different price, different narrative. That's the whole tell right there.

[Shah Trades @ShahTrades]

That instinct's usually fear dressed up as discipline. A support level breaking tells you about the last 50 trades, not the next 500. If nothing changed about the business or the thesis, one red candle through a line on a chart isn't new information, it's just people reacting to the same information differently. The only time it matters is if you were trading the level itself, not the company.

[Shah Trades @ShahTrades]

They'll say the FTC lawsuit and the Visa monitoring made this uninvestable. Real reason nobody bought under the 200 week is headline fatigue, this thing's been a legal circus for a year and most people can't tell noise from an actual business anymore. I'm holding because the lawsuits are about how they marketed GLP-1s, not whether 3 million people still want the product, and that's a legal problem, not a demand problem. Those price very differently once it clears.

[Shah Trades @ShahTrades]

Feels like a tacit admission same-store sales growth is getting harder to squeeze, so they're monetizing eyeballs instead of just burgers. Real question is whether this cannibalizes their own upsell prompts, that screen real estate currently sells extra fries, now it's competing with a Coke ad for attention.
$MCD

[Shah Trades @ShahTrades]

$NTRA up 63% since I called this out and the thesis just kept playing out exactly like I said it would. This was never a story stock, Signatera's becoming the default MRD test across oncology and the data keeps proving it out. Q2 revenue hit $752.8M, up almost 38% year over year, beat estimates by nine figures, and they raised full year guidance again. Stock just hit a new all time high near $369.

They just dropped the largest MRD lung cancer study ever run, over 1,100 patients, and it backs Signatera even harder in NSCLC. UBS just initiated with a Buy and a $435 target. That's real upside left if the MRD leadership holds.

What I'm watching next: more oncology indication expansion for Signatera, continued payor coverage wins, and whatever Q3 looks like when they report. Only thing keeping me a little careful here is the stock's priced for a lot of good news already, some models have it running well ahead of fair value now. The business is executing. The stock already knows it. Just don't be lazy about entry from here.

[Shah Trades @ShahTrades]

Fed hiked 25bps to 3.75-4.00% last week, first hike since 2023. Oil spike from Iran plus tariffs pushed inflation back up, and the labor market stayed tight enough that they felt safe moving. Bond market's been pricing this in for months, the 10-year's been near 5%.

For healthcare, this splits the sector. Cash-burning clinical-stage biotech gets squeezed hardest, distant cash flows discount harder and every future raise costs more. But healthcare demand doesn't really bend to rates, people still need drugs and diagnostics regardless, so the sector stays relatively defensive against the broader growth stock selloff.

What I'm watching: companies sitting on real cash get relatively more attractive since they're not touching capital markets right now. Commercial-stage names with actual revenue hold up better than pre-revenue names. And the M&A pace that's been red hot all year gets tested, leverage just got more expensive.

[Shah Trades @ShahTrades]

Fed hiked 25bps to 3.75-4.00% last week, first hike since 2023. Oil spike from Iran plus tariffs pushed inflation back up, and the labor market stayed tight enough that they felt safe moving. Bond market's been pricing this in for months, the 10-year's been near 5%.

For healthcare, this splits the sector. Cash-burning clinical-stage biotech gets squeezed hardest, distant cash flows discount harder and every future raise costs more. But healthcare demand doesn't really bend to rates, people still need drugs and diagnostics regardless, so the sector stays relatively defensive against the broader growth stock selloff.

What I'm watching: companies sitting on real cash get relatively more attractive since they're not touching capital markets right now. Commercial-stage names with actual revenue hold up better than pre-revenue names. And the M&A pace that's been red hot all year gets tested, leverage just got more expensive.

[Shah Trades @ShahTrades]

$NTRA up 63% since I called this out and the thesis just kept playing out exactly like I said it would. This was never a story stock, Signatera's becoming the default MRD test across oncology and the data keeps proving it out. Q2 revenue hit $752.8M, up almost 38% year over year, beat estimates by nine figures, and they raised full year guidance again. Stock just hit a new all time high near $369.

They just dropped the largest MRD lung cancer study ever run, over 1,100 patients, and it backs Signatera even harder in NSCLC. UBS just initiated with a Buy and a $435 target. That's real upside left if the MRD leadership holds.

What I'm watching next: more oncology indication expansion for Signatera, continued payor coverage wins, and whatever Q3 looks like when they report. Only thing keeping me a little careful here is the stock's priced for a lot of good news already, some models have it running well ahead of fair value now. The business is executing. The stock already knows it. Just don't be lazy about entry from here.

[Shah Trades @ShahTrades]

Feels like Anthropic's getting its story straight before the roadshow starts, lock in the supply chain now so nobody can ask awkward questions about compute costs later. That $517B number looks scary until you remember it's a ceiling, not a bill sitting in accounts payable. Whether it turns into a flex or a liability really just comes down to one thing, does revenue keep compounding faster than those commitments come due.

[Shah Trades @ShahTrades]

The real tell is Nvidia optimizing around supply instead of demand. That's not a company hedging, that's a company that can't get what it wants at any price. AMD's 432GB spec only matters if inference workloads are actually memory-bound rather than compute-bound, and right now that's still an open question, not a given.

[Shah Trades @ShahTrades]

$NVDA already put up to $10B into Anthropic last November tied to that $30B Azure compute deal. Now they're reportedly anchoring the actual IPO too, which is targeting a $2T valuation, the largest ever.

Revenue run rate went from $9B to $65B in seven months, so the growth is real. But Nvidia funding a company that's also one of its biggest customers is circular financing, dressed up as conviction. Fine while growth holds. Gets ugly the moment it doesn't.

[Shah Trades @ShahTrades]

$KRYS at 40% and the pipeline's what's actually getting interesting now. VYJUVEK did $119.2M in Q2, up 24% YoY, past $965M cumulative since launch, and they've already blown through their 60% US patient penetration target.

The real catalyst isn't the drug that's already approved, it's KB803 for ocular DEB lesions, fully enrolled with a readout before year end, and KB707, their inhaled lung cancer asset, putting up a 31% response rate with pembrolizumab. Management's framing the next 12-18 months as the shift from single-product to multi-product company, and the data's actually backing that up.

What I'm watching: Germany pricing talks are still unresolved and dinged European revenue this quarter, that needs to clear. Spain and Italy launches land before year end. KB803 and the cystic fibrosis readout in 2H are the real re-rating events, not the next print. $1.1B in cash means no dilution risk anytime soon either.

[Shah Trades @ShahTrades]

If this is real, it's a tell. Altman's basically saying they're bumping into something, whether that's capability risk, compute costs, or just diminishing returns on scale, and he knows not everyone will slow down with them. That's the actual problem with any coordinated pause, it only works if competitors agree, and $GOOGL, $META, and whoever else is racing isn't exactly incentivized to ease off if OpenAI does. Worth watching whether this is genuine caution or positioning ahead of something, companies don't usually announce restraint unless they want credit for it later.

[Shah Trades @ShahTrades]

September's opened with a real string of oncology wins. Revolution Medicines got Rasonque approved for pancreatic cancer and nearly doubled median survival in the trial, 13.2 months versus 6.7 on chemo, which is a rare thing to see in that disease. AbbVie's etentamig hit both primary endpoints for relapsed myeloma with a 74% response rate. Bristol Myers landed accelerated approval on Zenbexus, their first CELMoD therapy, another myeloma entrant. Multiple myeloma is turning into the most crowded, most competitive fight in oncology right now, worth watching how pricing and share shake out between BMY, ABBV and the rest of that field.

On the deal side, Roche paid $1.53B total for a trispecific antibody out of a Chinese biotech, and Lilly dropped $2.875B on Merida Biosciences for precision immunology. Big pharma's still buying pipeline instead of building it.

Rougher side of the month: Blueprint Medicines cut more than half its workforce, one of several biotechs doing deep layoffs recently. And Treasury just flagged $17.5B in suspected healthcare fraud today, that's a headline that'll have policy legs the rest of September.

What I'm actually watching through month end: $AXSM has its AXS-12 decision for Alzheimer's-related agitation coming, and from what's being modeled the approval odds aren't great, so that's real binary risk sitting on a stock that's already had a huge year. $MRK has a WINREVAIR update decision on the 21st. $NUVL has another lung cancer decision on the 18th. PDUFA season stacks up fast this time of year, and any one of those can move 20%+ in a day depending which way it breaks.

[Shah Trades @ShahTrades]

If this is real, it's a tell. Altman's basically saying they're bumping into something, whether that's capability risk, compute costs, or just diminishing returns on scale, and he knows not everyone will slow down with them. That's the actual problem with any coordinated pause, it only works if competitors agree, and $GOOGL, $META, and whoever else is racing isn't exactly incentivized to ease off if OpenAI does. Worth watching whether this is genuine caution or positioning ahead of something, companies don't usually announce restraint unless they want credit for it later.

[Shah Trades @ShahTrades]

$NVDA's not really betting on any one robotaxi winner, they're positioned as the toll collector regardless of who wins the race. Training, simulation, in-vehicle compute, that's the entire stack from R&D to deployment, and they're touching all three layers across every major program. That's the same playbook as the AI data center story just applied to a different vertical. The interesting part is what happens to margins once robotaxi fleets actually scale to millions of vehicles, that's a different economics problem than training clusters. In-vehicle compute is a hardware sale with real unit costs and competition from custom silicon, not the same moat as the data center business. Worth watching whether Tesla, Waymo, or whoever else pushes harder on vertical integration once volume justifies building their own chips. Right now Nvidia's essential because nobody's at scale yet. That changes at scale.

[Shah Trades @ShahTrades]

Rare disease competitive intelligence has been broken. Want to map a landscape? Cross-reference Orphanet, FDA designations, Drugs@FDA, and ClinicalTrialsgov. Four databases that don’t talk to each other. Hours of manual work.

We built Nexus Intelligence to fix that.

One searchable map: 63,433 disease-company-product connections. Everything sourced from public FDA and ClinicalTrialsgov data. Every connection has a confidence score and attribution. Search a disease and see every company working on it. Filter by stage. See which areas are crowded and which have zero activity. Export as CSV.

This matters for investors: rare disease is fragmented. You can’t spot white space or map competitive landscapes without tools like this. You can’t quickly build investment theses by hand.

Free. Public. No black box.

https://t.co/UtuQYeIOrc